Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,092 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV - Human Immunodeficiency Virus Clear all
Completed No phase listed Observational

Alveolar Macrophage Proteomics in HIV-associated Emphysema

NCT00823927
View directory record Official record
Conditions
HIV, Emphysema, HIV Infections
Interventions
Not listed
Lead sponsor
Philip Diaz
Other
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Cognitive Processing Intervention for Trauma, HIV/STI Risks, and Substance Use Among Native Women

NCT01849029
View directory record Official record
Conditions
Post Traumatic Stress Disorders, Unsafe Sex, Substance Use Disorders
Interventions
Cognitive Processing Therapy-Cognitive
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Toppenish, Washington
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Jun 25, 2026, 5:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons

NCT00889577
View directory record Official record
Conditions
HIV Infections, Coronary Artery Disease, Non-Alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Jun 25, 2026, 5:28 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

NCT07040319
View directory record Official record
Conditions
Hepatitis C
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Not applicable Interventional

A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children

NCT00001111
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Los Angeles, California • Farmington, Connecticut • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00002105
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal), Bleomycin sulfate, Vincristine sulfate
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Acute Effects of TCIG vs ECIG in PLWH

NCT04568395
View directory record Official record
Conditions
E Cigarette Use, Vaping, Smoking, Tobacco Smoking, Nicotine Use Disorder, Qt Interval, Variation in, HIV I Infection, Oxidative Stress, Inflammation
Interventions
TCIG, ECIG, sham control
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Jun 25, 2026, 5:28 PM EDT
Suspended Not applicable Interventional

Mindfulness Intervention for Individuals With HIV and Chronic Pain

NCT06481501
View directory record Official record
Conditions
Chronic Pain, HIV Infections
Interventions
ONE Mindfulness-Oriented Recovery Enhancement
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

NCT00074581
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Didanosine, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Stavudine, Tenofovir disoproxil fumarate, Zidovudine/Lamivudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
3,526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Peer-based Mobile-health Intervention to Increase Access & Adherence to Hepatitis C Treatment & HIV Viral Suppression

NCT02772328
View directory record Official record
Conditions
Hepatitis C, HIV, Risk Reduction Behavior
Interventions
Peer Mentor
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Study of Provider Computer Alerts Designed to Improve Delivery of HIV Care

NCT00678600
View directory record Official record
Conditions
HIV Infections
Interventions
Standard (static) Computer Alerts, Enhanced Computer Alerts
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Jun 25, 2026, 5:28 PM EDT
Completed No phase listed Observational

Long-term Follow-up of HIV Infected Patients Identified During Early Infection

NCT00086372
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Jun 25, 2026, 5:28 PM EDT
Completed No phase listed Observational

Evaluation of an HIV Outreach Program

NCT00300183
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

NCT00000872
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Days to 2 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Gainesville, Florida • New Orleans, Louisiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users

NCT00164372
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Peer Education Intervention
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
15 Years to 30 Years
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

NCT01815736
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs

NCT00099671
View directory record Official record
Conditions
HIV Infections
Interventions
Recombinant human interleukin-7
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Sacramento, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First in Human Study of TLC-ART 101 (ACTU 2001)

NCT05850728
View directory record Official record
Conditions
Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
Interventions
TLC-ART
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Jun 25, 2026, 5:28 PM EDT
Completed No phase listed Observational

The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women

NCT00006444
View directory record Official record
Conditions
HIV Infections, Papilloma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
49
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM

NCT00318409
View directory record Official record
Conditions
Substance Abuse, HIV Infections
Interventions
Bupropion, Placebo
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Jun 25, 2026, 5:28 PM EDT
Terminated Not applicable Interventional Results available

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

NCT00726830
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional

A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia

NCT00002067
View directory record Official record
Conditions
Anorexia, Cachexia, HIV Infections
Interventions
Megestrol acetate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Los Angeles, California • Oakland, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

NCT03639311
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, RPV LA, RPV, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals

NCT00002087
View directory record Official record
Conditions
HIV Infections
Interventions
Alvircept sudotox
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 25, 2026, 5:28 PM EDT